Reproductive Health Drugs Advisory Committee
January 23, 2007
Slides
On January 23 and 24, 2007, presentations and committee discussions addressed current issues which influence the consideration for approval of oral and non-oral (i.e., transdermal and intravaginal) hormonal contraceptive drug products. Implantable and injectable hormone products were not discussed. Issues for discussion included clinical trial design, expectations for efficacy and safety outcomes, and measures of acceptability of the product to the user, including cycle control.
Scott Monroe, M.D. (ppt) (htm)
Dr. Phill Price, M.D. (ppt) (htm)
Dr. James Trussell, Ph.D. 1st (ppt) (htm)
Dr. Daniel Gillen, Ph.D. (ppt) (htm)
Dr. Melissa Gilliam, M.D. (ppt) (htm)
Dr. Paula Adams Hillard, M.D. (ppt) (htm)
Dr. James Trussell, Ph.D. 2nd (ppt) (htm)
Up
| AC Home Page
